Novel Diagnostic and Prognostic for Crohn's Disease
This is a novel marker in blood that correlates to Crohn's diagnosis and endoscopic severity.
A test has been developed to measure soluble CD64 in blood via an ELISA. Soluble CD64 ≥39 ng/mL was 92% sensitive and 85% specific (AUC, 0.93) for diagnosis of new Crohn’s. Novel treatment strategies for Crohn's that result in complete mucosal healing sparked a shift from managing symptoms to preventing disease progression. Notwithstanding, preventing bowel injury entails accurately assessing gut inflammation. Current standards to assess disease activity include logging gastrointestinal symptoms, the physical exam, assessing biologic activity with laboratory biomarkers, abdominal cross-sectional imaging, and endoscopy. However, this assessment is either invasive or correlates poorly to endoscopic severity. In a clinical study, a total of 209 patients (72 controls, 76 new inflammatory bowel disease patients, and 61 established Crohn’s) were enrolled. Soluble CD64 was significantly elevated in new Crohn’s compared with controls. Soluble CD64 also differentiated endoscopic inactive, mild, moderate, and severe activity.
- Screening IBD patients for Crohn's
- Monitoring Crohn's patients and tracking endoscopic severity non-invasively
- More predictive than clinical symptoms
- Better correlation with endoscopic severity than CRP and ESR
- Convenient to measure on an ELISA platform
In the US, IBD currently affects ~1.6M people and ~70K new cases are diagnosed each year.
Phillip Minar, MD, Division of Gastroenterology, Hepatology and Nutrition